Biotech News

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

Pacira BioSciences (PCRX)Pacira BioSciences2026-03-30 12:00 ESTCompany update

-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

PCRXPacira BioSciences2026-08-07 12:00 EST

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRXPacira BioSciences2026-08-06 12:00 EST

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

PCRXPacira BioSciences2026-08-04 20:01 EST

Pacira BioSciences Reports Second Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-28 12:00 EST

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

PCRXPacira BioSciences2026-07-27 12:00 EST

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Stock data

Close: 24.67 USD
Market cap: 875.49M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States